Datasets:

xpertsystems
/

hc-end-002-sample

patient_id string	sex string	age_at_diagnosis_years float64	diabetes_duration_years float64	current_age_years float64	race_ethnicity string	insurance_type string	bmi_kg_m2 float64	weight_kg float64	height_cm float64	waist_circumference_cm float64	waist_hip_ratio float64	body_fat_pct float64	visceral_fat_index float64	hba1c_baseline_pct float64	hba1c_current_pct float64	hba1c_at_target_flag int64	hba1c_above_9_flag int64	fasting_glucose_mgdl float64	postprandial_glucose_mgdl float64	fasting_insulin_uIU_ml float64	homa_ir float64	homa_b_pct float64	c_peptide_ng_ml float64	beta_cell_function_pct float64	total_cholesterol_mgdl float64	ldl_mgdl float64	hdl_mgdl float64	triglycerides_mgdl float64	non_hdl_cholesterol_mgdl float64	uric_acid_mgdl float64	crp_mg_l float64	alt_iu_l float64	ast_iu_l float64	ggt_iu_l float64	adiponectin_ug_ml float64	leptin_ng_ml float64	thyroid_tsh_uIU_ml float64	sbp_mmhg float64	dbp_mmhg float64	hypertension_flag int64	hypertension_medication string	pharmacotherapy_line string	metformin_flag int64	metformin_dose_mg_day int64	metformin_hba1c_reduction_pct float64	sglt2_inhibitor_flag int64	sglt2i_drug string	sglt2i_hba1c_reduction_pct float64	sglt2i_weight_loss_kg float64	sglt2i_sbp_reduction_mmhg float64	glp1_agonist_flag int64	glp1_drug string	glp1_hba1c_reduction_pct float64	glp1_weight_loss_kg float64	glp1_nausea_flag int64	dpp4_inhibitor_flag int64	dpp4i_drug string	dpp4i_hba1c_reduction_pct float64	sulfonylurea_flag int64	sulfonylurea_drug string	su_hypoglycemia_events_per_year int64	su_weight_gain_kg float64	thiazolidinedione_flag int64	insulin_flag int64	insulin_type string	basal_insulin_units_per_day float64	total_daily_insulin_units float64	insulin_hba1c_reduction_pct float64	insulin_weight_gain_kg float64	medication_adherence_pct float64	polypharmacy_count int64	diet_pattern string	diet_quality_score float64	caloric_intake_kcal_day float64	carbohydrate_pct_intake float64	fiber_g_day float64	saturated_fat_pct float64	exercise_type string	exercise_frequency_per_week int64	exercise_minutes_per_session float64	sedentary_hours_per_day float64	vo2max_ml_kg_min float64	sleep_hours_per_night float64	sleep_quality_score float64	ahi_events_per_hour float64	obstructive_sleep_apnea_flag int64	smoking_status string	pack_years float64	alcohol_drinks_per_week int64	stress_score float64	weight_loss_intervention_flag int64	weight_change_kg_1yr float64	lifestyle_hba1c_modifier_pct float64	diabetes_stage string	insulin_resistance_index float64	retinopathy_stage string	retinopathy_tte_years float64	egfr_ml_min_173m2 float64	uacr_mg_g float64	microalbuminuria_flag int64	macroalbuminuria_flag int64	ckd_flag int64	esrd_flag int64	diabetic_neuropathy_flag int64	neuropathy_type string	dnss_score int64	mace_flag int64	cad_flag int64	stroke_flag int64	heart_failure_flag int64	peripheral_arterial_flag int64	nafld_flag int64	nash_flag int64	dyslipidemia_flag int64	statin_flag int64	statin_intensity string	depression_flag int64	phq9_score int64	cognitive_decline_flag int64	podiatric_complication_flag int64	bg_monitoring_frequency_per_day float64	cgm_use_flag int64	cgm_device string	diabetes_education_flag int64	endocrinology_referral_flag int64	pcp_visits_per_year int64	foot_exams_per_year int64	eye_exams_per_year int64	diabetes_distress_score float64	self_efficacy_score float64	health_literacy_score float64	social_support_score float64	financial_toxicity_flag int64	data_sku string	seed int64	generated_at string
HC002-0000001	Female	69.2	12.4	81.6	White	Medicare	32.3	81.8	159.3	69.5	0.852	37.1	2.6	7.1	5.7	1	0	105.3	178.1	33.2	8.63	64.2	2.53	26.4	176	88.7	49.9	187	126.1	4.6	4.38	168.8	129.6	93.6	6.7	40.1	2.42	136	89	1	Beta_blocker	Dual	1	1,000	1.17	0	null	0	0	0	0	null	0	0	0	0	null	0	1	Glyburide_5mg	2	2.5	0	0	null	0	0	0	0	65.4	8	Low_carb	72.9	1,434	29.5	19.1	14.3	Aerobic	2	46	6.2	23	7.2	4.9	16	1	Never	0	4	5.9	0	-2.3	-0.63	Uncontrolled	8.63	Severe_NPDR	8.1	49	200.1	1	0	1	0	1	Autonomic	4	0	0	0	0	0	1	0	1	1	Moderate	1	14	1	0	1	0	null	0	0	3	2	0	0.99	8	6.7	6.4	1	HC-END-002	42	2026-05-29T12:51:29Z
HC002-0000002	Male	53.1	4.3	57.4	Hispanic	Private	37	117.9	178.4	90	0.901	38.2	6.2	8.6	5.5	1	0	200	349.5	60	25	127.4	6.06	73.1	229.6	114.7	20	474.8	209.6	5.3	14.88	105.8	62.6	58.2	10.9	25.5	1.98	132	79	1	Thiazide	Dual	1	1,500	1.35	0	null	0	0	0	1	Dulaglutide_1.5mg	1.66	8.5	1	0	null	0	0	null	0	0	1	0	null	0	0	0	0	68.9	8	Western	69.4	2,182	46.6	17.5	15.4	Resistance	5	30	7.9	29.7	5.7	4.5	36.4	1	Current	5.7	5	5.5	0	9.6	-1.05	Uncontrolled	25	null	3.6	71.5	87.3	1	0	0	0	0	null	0	0	0	0	0	0	1	0	1	1	Moderate	1	15	0	0	0	0	null	1	1	4	1	1	0.49	3.2	2.9	6.5	1	HC-END-002	42	2026-05-29T12:51:29Z
HC002-0000003	Female	59	4.2	63.1	Black	Medicare	20.6	50.9	157.2	65	0.889	17.3	2	9.1	8.5	0	0	138.6	202.2	45.1	15.43	145.9	5.68	69	228.1	50	38	907.3	190.1	5.7	5.07	44.4	43.7	70.4	8.6	53	1.8	173	100	1	ACEi	Dual	0	0	0	0	null	0	0	0	0	null	0	0	0	0	null	0	1	Glyburide_5mg	2	3.2	0	0	null	0	0	0	0	77.5	6	Low_carb	67.5	1,839	23.3	21	13.5	null	0	8	7.3	17.9	7.4	2.2	10.6	1	Never	0	5	6.1	1	-6.2	-0.62	Uncontrolled	15.43	Mild_NPDR	2.3	103.6	52.6	1	0	0	0	0	null	0	0	0	0	0	0	1	0	0	0	null	1	16	0	0	5	0	null	1	0	2	0	2	2.24	6.3	4.7	5.9	1	HC-END-002	42	2026-05-29T12:51:29Z
HC002-0000004	Female	51.3	30	81.3	White	Private	46.8	114	156	101.8	0.908	56.6	7.3	7.8	5.5	1	0	135.2	250.5	29.4	9.82	2.1	0.31	1.9	160.6	73.6	49.2	188.8	111.4	4.1	3.55	99.3	63.1	64.1	10.5	49	5.85	133	93	1	Combination	Complex	0	0	0	0	null	0	0	0	1	Liraglutide_1.2mg	1.41	1.9	1	0	null	0	0	null	0	0	0	1	Premixed	30.5	50.2	1.21	2.8	67.9	7	Mixed	57.8	1,533	47	15.4	6.4	null	0	0	10.7	15	7.2	4.5	25.7	1	Never	0	3	5.5	0	-3.5	-0.64	Uncontrolled	9.82	DME	3.9	48.3	172.9	1	0	1	0	1	Autonomic	3	0	1	0	0	1	1	0	0	0	null	1	6	1	0	4	0	null	1	0	3	3	0	4.28	9.5	9.8	10	1	HC-END-002	42	2026-05-29T12:51:29Z
HC002-0000005	Male	50	1.1	51.1	Hispanic	Medicaid	32.3	84.5	161.7	75	1.049	28.6	0.6	9.7	7.8	0	0	196.3	307.4	20.1	9.73	125.9	5.94	72.2	245.6	175.4	33.3	184.2	212.3	4.9	6.14	63.4	41.5	102	6	22.4	1.81	182	91	1	ARB	Monotherapy	1	1,500	0.96	0	null	0	0	0	1	Liraglutide_1.2mg	1.65	7.3	0	0	null	0	1	Glipizide_10mg	3	1.6	0	0	null	0	0	0	0	68.7	7	Mixed	39.4	2,684	43.3	8	11.9	null	0	0	10.8	22.8	6.7	4.7	5.8	0	Never	0	2	4.9	0	-7.3	-0.18	Controlled	9.73	null	2.7	79	23.7	0	0	0	0	0	null	0	0	0	0	0	0	0	0	1	1	Moderate	1	13	0	0	3	0	null	1	0	7	4	2	3.61	5.6	8.4	7.4	0	HC-END-002	42	2026-05-29T12:51:29Z
HC002-0000006	Female	42.6	10.3	53	Black	Uninsured	39	97.8	158.3	84.9	0.882	49.9	7.1	8.6	6.4	1	0	134.1	235.7	41.9	13.87	75.9	3.49	43.1	186.7	102.5	42.4	209	144.4	6.5	5.53	63.9	30.6	28.7	7.3	38.3	1.92	156	76	1	Beta_blocker	Triple	0	0	0	1	Dapagliflozin_10mg	1.3	2.9	3.7	0	null	0	0	0	1	Alogliptin_25mg	1.15	0	null	0	0	0	1	Basal_only	45.8	82.3	3.37	0	43.3	9	DASH	85.6	1,574	35.7	22.8	9	Aerobic	2	50	7.5	29.2	7.3	4.1	18	1	Former	60	3	4.2	0	-2.1	0.3	Uncontrolled	13.87	Mild_NPDR	2	104.7	117.6	1	0	0	0	1	Peripheral	4	0	0	0	0	0	1	0	1	1	High	0	4	0	0	3	1	DexcomG7	0	0	3	2	1	1.96	3.4	9.1	6.5	0	HC-END-002	42	2026-05-29T12:51:29Z
HC002-0000007	Female	57.2	30	87.2	Black	Private	33	80	155.8	73.5	0.915	39.4	4	9.7	7.4	0	0	231.6	460.9	52.4	25	0	0.31	0	186.9	50	27.8	685.5	159.1	4.9	9.84	53.2	28.3	33.4	10.6	50.6	1.63	175	79	1	Beta_blocker	Triple	1	2,000	1.04	1	Empagliflozin_10mg	0.31	2.3	3.6	0	null	0	0	0	1	Linagliptin_5mg	0.3	1	Glimepiride_4mg	3	3.1	0	1	Basal_bolus	39.7	51	3.42	3.4	50.1	8	Western	30.5	2,257	54.2	8	14	null	0	5	7.8	15.2	7.6	3.5	42.8	1	Current	14.5	6	5.7	0	1.4	0.27	Uncontrolled	25	DME	18.9	55.8	298.9	1	0	1	1	1	Peripheral	3	1	0	0	0	0	1	1	1	1	Moderate	0	2	0	0	0	0	null	0	0	7	1	2	6	8.4	7.6	8.8	0	HC-END-002	42	2026-05-29T12:51:29Z
HC002-0000008	Female	41.8	5.5	47.2	Asian	Medicare	24.5	57.2	152.6	65	0.842	26.6	1.8	8.7	7.6	0	0	158.9	209.1	42.8	16.81	121.2	5.47	61	188.8	50	64.3	384.9	124.4	4.9	6.28	53	35.7	23.5	13.4	22.6	2.24	160	83	1	Thiazide	Monotherapy	1	1,000	1.41	0	null	0	0	0	0	null	0	0	0	0	null	0	1	Glipizide_5mg	3	1.9	0	0	null	0	0	0	0	59.2	7	Mixed	64	1,764	40.9	14.1	10	Aerobic	4	36	7	29.6	7.9	3.8	20.3	1	Never	0	5	3.7	0	4.3	-0.3	Controlled	16.81	null	5.5	67.2	258.6	1	0	0	0	0	null	0	0	0	0	0	0	1	1	1	1	Moderate	0	5	0	0	3	0	null	1	0	3	1	0	1.3	6.5	7.1	9	0	HC-END-002	42	2026-05-29T12:51:29Z
HC002-0000009	Male	60	24	84	White	Medicaid	32.9	98.5	172.9	75.2	0.931	29.9	4.7	9	8.3	0	0	176.1	318.2	29	12.62	0	0.46	1.6	187.6	118.6	25	220	162.6	7	3.77	61.2	51.6	59.3	11.9	18.9	2.1	166	82	1	ACEi	Dual	1	500	0.38	0	null	0	0	0	0	null	0	0	0	0	null	0	0	null	0	0	0	0	null	0	0	0	0	46.9	4	Mediterranean	79.3	1,707	35.4	26.7	5.3	null	0	6	8.9	29.8	6.9	4	33.5	1	Never	0	3	3.2	0	-2.2	-0.51	Insulin_requiring	12.62	PDR	12.7	18.7	380	0	1	1	0	0	null	0	1	0	0	0	0	1	0	1	1	High	1	15	0	0	5	0	null	1	0	5	0	0	3.57	6.1	8.6	7.7	0	HC-END-002	42	2026-05-29T12:51:29Z
HC002-0000010	Male	65	5.3	70.3	Asian	Private	33	110	182.7	82.8	0.988	29.2	1.5	7.4	6.1	1	0	126.7	184.5	45.3	14.19	114.6	4.92	59.6	100	50	21	299.7	79	5.4	16.81	102.9	85.4	24.5	6.3	18.5	1.33	177	99	1	Thiazide	Monotherapy	0	0	0	1	Canagliflozin_100mg	0.99	3.4	2.8	0	null	0	0	0	0	null	0	0	null	0	0	0	0	null	0	0	0	0	57.7	5	Western	42.6	1,907	55.3	8	11.1	Aerobic	3	51	8.8	27.7	6.5	5.6	34.7	1	Never	0	4	6	0	4.5	-0.74	Insulin_requiring	14.19	null	7.2	81.6	312	0	1	0	0	0	null	0	0	0	0	0	0	1	0	1	1	Moderate	1	11	0	0	3	0	null	1	0	2	1	0	2.06	5.4	8.5	8.8	0	HC-END-002	42	2026-05-29T12:51:29Z
HC002-0000011	Male	56.4	30	86.4	White	Medicaid	32.4	103.7	178.9	78.8	0.937	28.8	2.5	7.4	5.5	1	0	149.8	232.4	87.3	25	9.1	0.1	0	178	76.5	29.3	360.7	148.7	5.6	13.25	105.2	73.5	40.2	7.1	20.8	1.82	137	86	1	ARB	Dual	1	1,000	0.83	0	null	0	0	0	0	null	0	0	0	0	null	0	0	null	0	0	0	1	Basal_only	37.5	48	2.8	4.7	83.3	7	Western	42.1	2,231	52.7	13.2	14.3	null	0	20	4.3	18.6	7.1	6.8	43.5	1	Current	20.9	0	7.5	0	0.8	-1.46	Uncontrolled	25	PDR	11.5	34.2	377.4	0	1	1	1	1	Both	1	1	0	0	0	0	1	0	1	1	High	0	2	0	0	3	0	null	1	0	5	1	0	4.5	8	7.2	8	0	HC-END-002	42	2026-05-29T12:51:29Z
HC002-0000012	Female	48.6	2.1	50.7	White	Medicare	33.1	82.7	158	71.5	0.876	33.2	4.3	10.4	8.9	0	0	247.7	329.8	43.2	25	118.2	5.38	65.1	133.2	50	43.7	588.3	89.4	5.5	18.06	200	136.7	31.6	2.6	31.1	2.89	143	68	1	Combination	Insulin_based	1	1,000	1.16	0	null	0	0	0	0	null	0	0	0	0	null	0	0	null	0	0	0	0	null	0	0	0	0	90.9	7	DASH	74.7	2,009	42.9	19.3	6.5	Aerobic	4	43	5.5	31.6	8.2	7.1	15.9	1	Never	0	2	3.9	1	-0.1	-0.41	Complication_burden	25	null	2	90.9	58.9	1	0	0	0	0	null	0	0	0	0	0	0	1	0	0	0	null	0	3	0	0	4	0	null	1	0	1	1	1	2.64	5.1	6.7	6.9	0	HC-END-002	42	2026-05-29T12:51:29Z
HC002-0000013	Female	57.4	7.6	65	White	Uninsured	28.3	76	163.8	65	0.796	28.5	0	9.4	7.2	0	0	165.5	240.5	14.7	6.02	111.6	4.76	59.8	246.8	50	44	770.7	202.8	3.3	7.38	78.8	42.7	140.1	7.2	38.5	3.49	131	74	1	Beta_blocker	Dual	1	1,500	1.43	0	null	0	0	0	0	null	0	0	0	0	null	0	0	null	0	0	0	0	null	0	0	0	0	89.5	7	Vegan	78.4	1,752	47.7	19.6	5.5	Mixed	5	49	4.5	23.6	7.6	2.4	31.5	1	Never	0	2	4.3	0	1.5	-0.91	Complication_burden	6.02	null	7.9	73.4	437.1	0	1	0	0	1	Peripheral	1	0	0	0	0	1	0	0	1	0	null	0	2	0	0	2	0	null	1	0	4	1	2	2.47	9.1	8.6	8.9	0	HC-END-002	42	2026-05-29T12:51:29Z
HC002-0000014	Female	48.3	10.3	58.6	Hispanic	Uninsured	32.2	86.5	163.9	71.3	0.807	35.4	3	6.8	5.5	1	0	166.2	363.7	42.6	17.49	69.1	3.45	41.8	245.3	111.3	30.9	515.5	214.4	5.4	6.72	89.4	66.5	33.5	11.1	31.1	2.22	118	96	1	Beta_blocker	Dual	1	1,000	1.75	1	Empagliflozin_25mg	0.68	2.1	3.5	0	null	0	0	0	0	null	0	0	null	0	0	0	0	null	0	0	0	0	78.2	7	Mixed	61.6	1,611	39.2	13.7	14.1	Aerobic	6	39	4	30.4	6.4	2.8	60	1	Never	0	5	2.1	0	5.3	0.33	Insulin_requiring	17.49	null	15.5	80.3	127.6	1	0	0	0	1	Peripheral	5	0	0	0	0	0	1	0	1	1	Moderate	0	3	0	0	1	1	Libre3	1	0	2	2	0	4.15	6.4	4.2	4.8	0	HC-END-002	42	2026-05-29T12:51:29Z
HC002-0000015	Male	63.2	19.5	82.8	White	Private	32.9	98.9	173.4	75.7	0.998	28.3	3.4	8.7	6.5	1	0	140.1	308	118.3	25	27.4	1.14	16.1	217.4	98.6	20	493.9	197.4	5.3	10.59	70.1	47.1	28.3	10.1	25.1	2.26	141	84	1	Beta_blocker	Dual	1	2,000	0.99	1	Empagliflozin_25mg	0.71	3.2	1.8	0	null	0	0	0	0	null	0	1	Glipizide_10mg	4	1.8	0	1	Basal_only	29.4	35.9	0.9	3.5	65.5	10	Mixed	41.3	2,847	47	13.1	8.5	Resistance	1	45	7.5	24.5	6.9	5.4	19.2	1	Never	0	4	2.9	0	1.2	-0.52	Complication_burden	25	Severe_NPDR	16.5	74.6	75.9	1	0	0	0	0	null	0	0	1	0	0	1	1	0	0	0	null	0	0	0	0	2	0	null	1	0	5	2	0	2.57	8.2	5.8	4.8	0	HC-END-002	42	2026-05-29T12:51:29Z
HC002-0000016	Male	30	12.3	42.3	White	Medicare	42.8	143.2	183	102.8	1.013	40.2	8.2	5.5	5.5	1	0	113.6	221.3	21.4	6	67.2	2.04	24.5	175.9	112.8	29.1	170.5	146.8	7.2	5.75	38.6	37.1	80.3	5.4	33.9	1.87	186	82	1	ARB	Dual	1	2,000	1.43	1	Canagliflozin_100mg	0.64	2.8	3.2	1	Semaglutide_0.5mg	2.32	5	1	0	null	0	1	Glimepiride_2mg	5	3.1	0	0	null	0	0	0	0	87.4	7	DASH	65.1	2,820	45.2	20.3	6.3	Aerobic	7	45	4	44.3	8.8	7.4	10.4	0	Current	60	0	2.9	0	-2.3	0.05	Insulin_requiring	6	null	18.9	29.2	174.1	1	0	1	0	0	null	0	0	0	0	0	0	1	0	1	1	High	1	11	0	0	4	0	null	1	1	4	1	2	3.83	8	3.4	7.8	0	HC-END-002	42	2026-05-29T12:51:29Z
HC002-0000017	Female	48	21.9	69.9	Black	Medicare	30.3	84.2	166.7	65	0.801	32.4	0	7.5	5.5	1	0	147.1	272.2	37.8	13.71	21.5	0.36	8	146.7	62.2	46.7	188.9	100	5.8	7.17	50.1	32.3	163	14.7	61.4	1.75	150	99	1	ACEi	Complex	1	2,000	1.38	0	null	0	0	0	0	null	0	0	0	0	null	0	0	null	0	0	0	1	Concentrated	24.4	25.2	1.33	1.5	78.3	7	Mixed	67.6	1,376	46.3	12.4	14.4	null	0	10	8.2	17.4	7.7	3.4	13	0	Never	0	1	7.4	0	2.3	-0.69	Uncontrolled	13.71	PDR	10.9	56.5	69.1	1	0	1	0	0	null	0	0	0	0	0	1	1	0	1	1	Moderate	1	12	0	0	2	0	null	1	0	1	1	0	2.65	3.8	4.4	5.4	0	HC-END-002	42	2026-05-29T12:51:29Z
HC002-0000018	Male	30	2.2	32.2	White	Private	27.9	82.1	171.5	75	1	22	4.9	9.9	7.9	0	0	147.6	295.1	31.7	11.57	136.2	5.68	72.8	160	50	24.6	436.2	135.4	6.7	5.71	44.1	34.8	53.5	6.7	11.5	1.45	180	71	1	Thiazide	Dual	1	2,000	1.32	0	null	0	0	0	0	null	0	0	0	0	null	0	0	null	0	0	1	0	null	0	0	0	0	92	7	Western	37.1	2,869	47.6	15.2	13.4	Aerobic	3	41	6.5	34.5	7	4.8	23.5	1	Never	0	3	2	0	2.2	-0.81	Controlled	11.57	null	8.2	73.1	76.8	1	0	0	0	0	null	0	0	0	0	0	0	1	0	1	1	High	1	14	0	0	1	1	Libre2	0	0	5	0	2	0	7.2	7	8.5	0	HC-END-002	42	2026-05-29T12:51:29Z
HC002-0000019	Female	34.1	22.8	56.9	White	Private	29.5	76.1	160.5	65.6	0.828	30.6	0.7	8.2	5.7	1	0	153.4	323.2	38.8	14.68	15.6	1.26	10.8	258.8	119.3	41.7	489	217.1	3.2	2.72	18.7	13.3	57.3	5.7	19.6	1.09	191	60	1	Thiazide	Triple	1	1,000	1.09	1	Empagliflozin_25mg	0.77	3.4	4.6	0	null	0	0	0	0	null	0	1	Glipizide_10mg	1	2.1	0	1	Basal_bolus	18.8	34	1.88	3	66	7	Western	31.1	1,911	47.5	8	14.1	Aerobic	1	50	9.4	26.5	8.2	3.4	6.8	1	Current	4.8	0	6.4	0	0.4	-0.04	Uncontrolled	14.68	Mild_NPDR	18.1	52.3	175.3	1	0	1	0	0	null	0	0	0	0	0	0	0	0	0	0	null	0	4	0	0	2	1	null	1	1	3	1	0	5.82	5.7	8.2	7.3	0	HC-END-002	42	2026-05-29T12:51:29Z
HC002-0000020	Female	68.4	30	90	White	Uninsured	32.8	83.8	159.9	67	0.861	35.6	1	8.6	6.8	1	0	154.8	273.6	42.7	16.33	0	0.1	0	158.7	55.2	41	312.2	117.7	5	7.49	43	31.1	132.9	5.9	53.3	1.6	200	78	1	Combination	Monotherapy	1	1,500	0.94	1	Canagliflozin_300mg	1.12	2	4.9	0	null	0	0	0	0	null	0	0	null	0	0	0	0	null	0	0	0	0	76.3	7	Western	47.4	1,709	51.1	15.1	13.6	Resistance	7	38	5	21.8	6.1	4.5	12.3	0	Current	2.2	5	5	0	4.1	-0.23	Uncontrolled	16.33	DME	29.3	46.1	485	0	1	1	0	1	Both	2	1	0	0	0	1	1	0	1	1	High	1	9	1	0	3	0	null	1	1	6	2	2	3.53	7.5	10	10	0	HC-END-002	42	2026-05-29T12:51:29Z
HC002-0000021	Female	62.7	20.5	83.2	White	Private	33.3	78.7	153.8	78.9	0.945	40.3	1.1	5.5	5.5	1	0	84.9	113.1	72.3	15.16	28.3	1.2	14.3	100	50	42.9	634.3	70	3.7	5.37	156.3	113.7	104.3	4.5	24.2	3.3	187	89	1	Thiazide	Monotherapy	1	2,000	0.67	0	null	0	0	0	0	null	0	0	0	1	Alogliptin_25mg	0.76	0	null	0	0	0	0	null	0	0	0	0	82	5	Low_carb	72	1,724	18.7	15.9	13.4	null	0	0	5.6	16.2	7.2	3.6	16.1	1	Never	0	5	6.7	0	-5.9	-0.21	Complication_burden	15.16	DME	9.3	53	513.4	0	1	1	0	0	null	0	1	0	0	0	0	1	0	1	1	High	0	5	1	0	3	1	Libre2	0	0	1	1	1	2.37	6.1	6.3	4.7	0	HC-END-002	42	2026-05-29T12:51:29Z
HC002-0000022	Male	43.4	5.5	48.9	White	Medicare	31.7	103.9	181.1	75	1.008	23.1	0.9	7.8	6.8	1	0	149.2	289.2	39.6	14.61	112.7	5.38	61.1	224.1	123.4	28.3	362.5	195.9	6.2	5.88	82.4	76.8	77.9	9.3	19.7	1.82	189	80	1	Beta_blocker	Dual	0	0	0	1	Empagliflozin_25mg	0.61	1.5	5.7	0	null	0	0	0	0	null	0	0	null	0	0	0	0	null	0	0	0	0	82.4	6	Mixed	34.4	2,481	45.5	8	6.9	HIIT	1	41	9.2	26.1	9.1	5.8	20.4	1	Never	0	2	7.8	0	2.1	-0.46	Complication_burden	14.61	null	10.4	56.4	90.9	1	0	1	0	1	Peripheral	5	0	0	0	0	0	1	0	1	1	High	0	6	0	0	1	0	null	0	0	4	2	2	4.71	2.4	5.6	8.8	0	HC-END-002	42	2026-05-29T12:51:29Z
HC002-0000023	Female	34	3.3	37.2	White	Medicaid	43.1	108	158.3	96.1	0.908	49.1	5.2	8.9	7.9	0	0	165.2	361.2	87.9	25	143.9	6.4	73.5	242	54.2	41.9	729.8	200.2	2.3	10.17	72.8	47.2	49	6.2	49.3	1.88	155	64	1	CCB	Insulin_based	1	2,000	1.24	0	null	0	0	0	0	null	0	0	0	0	null	0	1	Glyburide_5mg	2	2.9	0	0	null	0	0	0	0	90.4	5	Vegan	83.8	2,381	48.1	18.8	5.6	Resistance	5	23	11.3	30.8	7.6	3	60	1	Current	4	1	5.4	0	3.4	0.07	Uncontrolled	25	null	5.6	55.5	95.4	1	0	1	0	1	Peripheral	5	0	0	0	0	0	1	1	1	1	High	1	13	0	0	1	0	null	0	0	6	0	0	1.45	7.8	6.3	5.8	0	HC-END-002	42	2026-05-29T12:51:29Z
HC002-0000024	Female	30	4.5	34.5	White	Private	28.2	68	155.3	65	0.975	29.9	0	9.1	7.2	0	0	162.5	248.9	33.8	13.58	105.3	5.19	59.4	248.1	127.9	41.6	392.6	206.4	3.3	13.7	79.6	61	75.7	9.9	41.1	1.87	149	95	1	ACEi	Monotherapy	1	500	1.08	0	null	0	0	0	1	Semaglutide_0.5mg	1.27	2.9	1	0	null	0	0	null	0	0	0	0	null	0	0	0	0	80.9	8	Mixed	51.6	1,922	39.7	12.6	11.1	Aerobic	6	43	8.2	35	8.7	2.9	27	1	Never	0	5	7.8	0	-3.3	-0.01	Uncontrolled	13.58	null	5.9	46.6	196.2	1	0	1	0	0	null	0	0	0	0	0	0	1	1	1	1	Moderate	0	5	0	0	3	0	null	1	1	1	2	1	1.52	1.7	7	7.4	0	HC-END-002	42	2026-05-29T12:51:29Z
HC002-0000025	Female	45.5	1.8	47.3	Black	Medicare	38.6	104.6	164.6	85.7	0.818	44	4.7	9.9	7.5	0	0	176.7	303.5	34.1	14.86	107.1	5.13	60.4	224.5	124.7	32.8	335.1	191.7	6.5	4.59	27.5	20.8	29.1	5.3	78.3	3.85	153	84	1	ACEi	Dual	1	1,500	0.93	0	null	0	0	0	0	null	0	0	0	0	null	0	0	null	0	0	0	0	null	0	0	0	0	80.4	5	Mediterranean	80.5	1,470	38.9	22.2	6	HIIT	1	34	9.9	23.6	6.7	9	11	0	Never	0	1	8.6	0	-3.4	-1.71	Complication_burden	14.86	null	5.1	80.1	48.3	1	0	0	0	0	null	0	0	0	0	0	0	0	0	1	0	null	0	1	0	0	4	0	null	1	1	3	0	0	0.82	6.5	10	8.3	1	HC-END-002	42	2026-05-29T12:51:29Z
HC002-0000026	Male	75	15.6	90	Other	Uninsured	23.3	72	175.6	75	0.901	18.4	1.5	8.1	5.5	1	0	142.8	232.1	23.3	8.22	39.4	1.81	19.2	230.7	156.4	40	171.3	190.7	6.6	4.74	64.3	37	36.9	8.3	39.6	1.45	148	90	1	CCB	Dual	0	0	0	1	Canagliflozin_100mg	0.94	1.9	4.9	1	Semaglutide_1.0mg	2.42	7.9	1	1	Linagliptin_5mg	0.43	0	null	0	0	0	1	Basal_bolus	43.6	86.3	2.72	4.8	62.1	9	Low_carb	62.1	1,668	27.9	13.2	12.7	null	0	0	8.6	15	6.2	4.2	60	1	Never	0	5	8.2	0	4	-0.55	Insulin_requiring	8.22	Severe_NPDR	10.3	71.5	189.2	1	0	0	0	0	null	0	0	0	0	0	0	0	0	1	1	Moderate	0	2	0	0	0	1	Libre3	1	0	4	0	0	2.52	10	6.5	7.6	0	HC-END-002	42	2026-05-29T12:51:29Z
HC002-0000027	Male	57.2	11.4	68.6	Hispanic	Medicare	29.4	88.3	173.3	75	0.917	24.3	0.7	8.1	5.5	1	0	137.1	226.3	13.5	4.57	51.5	3.08	32	187	105.3	42.7	195.3	144.3	5.8	4.12	104.4	90.3	138.1	3.2	12.5	2.49	151	89	1	ACEi	Triple	1	2,000	1.02	0	null	0	0	0	1	Liraglutide_1.8mg	1.41	5.2	0	1	Sitagliptin_100mg	0.88	0	null	0	0	1	0	null	0	0	0	0	89.5	9	Western	40.6	2,599	51.7	12.8	15.6	Mixed	3	50	6.5	30.7	8.2	8.3	18.1	1	Former	30	2	4.2	0	4.5	0.21	Uncontrolled	4.57	null	16.5	60.5	208	1	0	0	0	1	Peripheral	5	0	1	1	0	1	1	0	1	1	Moderate	0	1	0	0	2	0	null	1	0	4	0	0	1.87	9	4.1	7.9	0	HC-END-002	42	2026-05-29T12:51:29Z
HC002-0000028	Male	45.3	11.4	56.7	Black	Private	33.6	93.3	166.5	84.3	0.945	26.1	2.6	6.3	5.5	1	0	115.7	225.6	45.2	12.91	84	3.56	41.2	106.1	50	33.1	487.3	73	5.1	4.28	63.7	54.5	135.2	8.1	23.7	2.13	163	69	1	Thiazide	Triple	0	0	0	0	null	0	0	0	0	null	0	0	0	1	Linagliptin_5mg	0.67	0	null	0	0	0	0	null	0	0	0	0	69.8	7	Low_carb	40	2,776	19.4	13.2	12.9	null	0	0	7.9	30.6	4.6	5.6	7.2	0	Never	0	1	1.6	0	5.1	-1.01	Complication_burden	12.91	null	19	79.8	85	1	0	0	0	0	null	0	0	0	0	0	0	1	0	1	1	Moderate	1	11	0	0	3	0	null	1	1	2	1	0	2.39	7	7.3	7.7	0	HC-END-002	42	2026-05-29T12:51:29Z
HC002-0000029	Male	57.6	13.8	71.4	Asian	Private	25.4	72.1	168.3	75	0.819	22.4	3	8.1	5.5	1	0	129.4	212.3	107.5	25	30	0.77	15.8	186.1	62	42.1	409.7	143.9	4.9	4.24	31.9	20.5	72	8.5	13.9	2.27	140	88	1	CCB	Triple	1	2,000	0.99	0	null	0	0	0	1	Liraglutide_1.8mg	0.5	6.4	1	1	Sitagliptin_100mg	0.51	1	Glipizide_5mg	1	2.8	0	0	null	0	0	0	0	95.3	8	Low_carb	51.3	2,196	15.6	25.5	15.6	Aerobic	0	49	9.5	20.7	7	2.1	9.1	1	Never	0	3	5.3	0	-1.1	-1.42	Insulin_requiring	25	Severe_NPDR	13.2	63.4	169.6	1	0	0	0	0	null	0	0	0	0	0	0	1	0	1	1	High	0	4	0	0	3	0	null	1	0	4	0	2	0.74	5.2	6.7	6.3	0	HC-END-002	42	2026-05-29T12:51:29Z
HC002-0000030	Female	33.3	30	63.3	Other	Uninsured	32.9	84.5	160.2	70.8	0.848	34.3	1.7	6.4	5.5	1	0	185.3	397.8	49.5	22.65	0	0.1	1.3	208.6	50	42.1	584.7	166.5	5.3	6.18	64.2	44.2	19.3	4.5	25.6	2.46	132	99	1	ARB	Dual	1	1,000	1.43	0	null	0	0	0	0	null	0	0	0	0	null	0	1	Glipizide_10mg	1	0.5	0	1	Basal_only	56.7	57.7	4.08	3.8	83.4	7	Mediterranean	80.9	1,842	38	26.8	7.1	null	0	0	6.7	24.5	8	5.6	10.5	0	Former	9	3	5.9	1	2	-0.48	Controlled	22.65	Severe_NPDR	9.4	45.6	366.4	0	1	1	0	1	Peripheral	8	0	0	0	0	0	0	0	1	1	High	0	4	0	0	1	0	null	0	1	1	1	0	1.84	6.1	6.4	8.6	0	HC-END-002	42	2026-05-29T12:51:29Z
HC002-0000031	Female	48.4	1	49.4	Hispanic	Private	35.4	88.2	157.9	75.8	0.827	39.7	2.6	5.5	5.5	1	0	76.8	154.5	57.9	10.98	155.3	6.98	81.3	179.9	85.5	56.9	187.2	123	4.7	10.3	125.9	88.9	30.7	6.4	31.8	2.26	153	96	1	Thiazide	Monotherapy	1	2,000	0.69	0	null	0	0	0	0	null	0	0	0	1	Saxagliptin_5mg	0.93	0	null	0	0	0	0	null	0	0	0	0	71.6	7	Western	66.5	2,246	40.5	23.7	15	Mixed	5	76	6.9	36.2	7.5	2.8	9.1	1	Current	10.1	2	1.6	0	2	-0.09	Controlled	10.98	null	5.7	53.1	205.2	1	0	1	0	0	null	0	0	0	0	0	0	1	0	1	1	Moderate	1	6	0	0	1	1	Libre3	1	0	6	2	2	3.44	8.3	5.9	8.7	0	HC-END-002	42	2026-05-29T12:51:29Z
HC002-0000032	Female	53.2	7.3	60.5	Asian	Medicare	36.5	100.1	165.6	81.6	0.907	41.5	4.2	6.7	5.5	1	0	108	143	32.1	8.55	86.7	4.21	52.7	178.1	68.1	33.8	381.1	144.4	7	8.95	73	37.6	42.7	5.9	41.3	3.14	136	92	1	Beta_blocker	Triple	1	2,000	1.18	1	Empagliflozin_10mg	0.63	0.8	3.5	0	null	0	0	0	0	null	0	0	null	0	0	0	0	null	0	0	0	0	51.7	5	Western	39.4	2,149	54.7	8	15	Aerobic	5	42	5.2	29.1	4.3	2.7	28.3	1	Never	0	2	5.6	1	0.3	-0.68	Insulin_requiring	8.55	Mild_NPDR	6.9	65.8	43.3	1	0	0	0	0	null	0	0	0	0	0	0	1	0	1	1	High	0	5	0	0	4	0	null	1	0	5	2	2	4.71	4.6	10	6.1	0	HC-END-002	42	2026-05-29T12:51:29Z
HC002-0000033	Male	51	3.5	54.5	Other	Private	32.2	98.4	174.7	75	0.981	25.7	4.1	10.8	10.2	0	1	177.7	361.9	33.3	14.62	139.7	6.37	70.6	148.4	50	24	413.7	124.3	6	3.64	33.9	17.1	54.8	14.5	31.3	2.17	135	89	1	ACEi	Dual	0	0	0	0	null	0	0	0	1	Semaglutide_0.5mg	1.17	4.7	0	0	null	0	0	null	0	0	0	0	null	0	0	0	0	82.2	6	Mixed	41.7	2,647	39.6	8	10.5	Aerobic	6	33	4	35.4	5.2	0.8	3.9	0	Never	0	3	0.4	0	1.5	0.38	Controlled	14.62	null	5.1	95	90.7	1	0	0	0	1	Autonomic	5	0	0	0	0	0	1	0	1	1	Moderate	0	2	0	0	2	1	Libre3	1	0	6	3	2	2.86	7	5.4	5.2	0	HC-END-002	42	2026-05-29T12:51:29Z
HC002-0000034	Male	61.5	17.7	79.2	Asian	Medicare	31.8	105.3	182	75	0.924	28.6	2	8	8.7	0	0	207.1	413.2	65.1	25	18.2	0.87	10.6	146.9	63.4	23.6	299.8	123.4	6.3	14.81	200	142.6	28.5	4.7	42.4	4.82	149	65	1	CCB	Dual	0	0	0	0	null	0	0	0	0	null	0	0	0	0	null	0	0	null	0	0	0	0	null	0	0	0	0	83.6	4	DASH	69.6	1,494	53.2	18.7	9.3	Mixed	4	36	5.6	27.2	6.7	2	34.5	1	Former	25.6	4	8.6	0	1.4	0.71	Complication_burden	25	null	3.6	84.5	729.4	0	1	0	0	1	Autonomic	4	0	1	0	0	0	0	0	1	1	Moderate	0	2	0	0	3	0	null	0	0	2	0	1	2.1	4.5	3.1	7.4	1	HC-END-002	42	2026-05-29T12:51:29Z
HC002-0000035	Male	56.1	30	86.1	Hispanic	Uninsured	35.3	117.7	182.6	76.6	0.995	35.6	1.1	8.8	5.5	1	0	124.2	219.2	119.7	25	14.8	0.1	0	254.8	141.7	20	465.6	234.8	4.5	12.76	44.4	29.1	54.6	7.7	36.6	2.24	151	88	1	Combination	Dual	1	500	0.98	0	null	0	0	0	0	null	0	0	0	0	null	0	0	null	0	0	1	1	Basal_only	21.7	21.8	1.78	4.8	87	9	Mediterranean	61.3	2,394	33.2	24.7	8.6	null	0	7	11.5	18.4	7.4	3.4	33.2	1	Never	0	6	6.5	0	3.2	-1.56	Complication_burden	25	PDR	19.7	40.9	750.4	0	1	1	0	1	Peripheral	2	0	0	0	0	0	1	0	0	0	null	0	6	0	1	1	0	null	1	1	3	2	0	3.68	5.6	5.2	7.2	0	HC-END-002	42	2026-05-29T12:51:29Z
HC002-0000036	Male	60	4.8	64.9	White	Medicare	24.2	72.8	173.4	75	1.003	19.5	2.6	7.6	6.9	1	0	147.3	257.3	77.3	25	139.3	6.07	68.8	256.2	79.6	20	783.1	236.2	5.8	3.44	67.8	52.1	157	5.4	32.7	1.02	164	71	1	ARB	Monotherapy	0	0	0	0	null	0	0	0	0	null	0	0	0	0	null	0	0	null	0	0	1	0	null	0	0	0	0	76.7	6	Mixed	65	2,205	47.3	28.5	8.6	HIIT	3	19	7.8	28.1	7.4	3.9	12.5	1	Former	60	3	3.9	0	-0.7	-0.63	Controlled	25	null	6.4	88.2	115.3	1	0	0	0	1	Peripheral	3	0	0	0	0	0	0	0	1	1	High	0	5	0	0	1	0	null	1	0	6	2	0	4.45	5.3	5.4	3.4	1	HC-END-002	42	2026-05-29T12:51:29Z
HC002-0000037	Male	43.7	9	52.7	White	Uninsured	27.7	88.8	179.2	75	0.914	20.4	3.2	5.5	5.5	1	0	104.2	213.8	55.8	14.35	80.6	3.85	46.9	184.9	111.2	33.4	201.6	151.5	6.4	13.17	39.2	15.7	72.7	6.3	13.3	2.93	144	99	1	Beta_blocker	Dual	1	2,000	1.14	0	null	0	0	0	0	null	0	0	0	0	null	0	0	null	0	0	0	1	Basal_only	29.9	35.5	3.67	3.6	97.1	8	Mediterranean	72.6	1,915	34.3	18	9.5	Aerobic	4	33	4	36.7	6.8	4.5	30.6	1	Never	0	6	5.8	0	4.8	-1.77	Uncontrolled	14.35	Moderate_NPDR	6.2	96.1	136.7	1	0	0	0	1	Autonomic	8	1	0	0	0	0	1	1	0	0	null	0	3	0	0	6	0	null	0	0	6	0	1	4.37	7	3.7	7.3	0	HC-END-002	42	2026-05-29T12:51:29Z
HC002-0000038	Male	62.8	0.7	63.5	Hispanic	Private	34.2	102.9	173.3	76	0.93	31.5	0.4	9.9	8.3	0	0	189.2	318.3	39.9	18.63	127.3	6.34	75.5	195.7	109.5	34.3	259.1	161.3	5.8	8.65	44.6	25.9	71.2	7.7	23.3	2.62	166	96	1	CCB	Monotherapy	1	1,000	0.55	1	Empagliflozin_10mg	0.64	1.4	1.7	0	null	0	0	0	1	Sitagliptin_100mg	0.56	1	Glipizide_5mg	1	2.1	0	0	null	0	0	0	0	91.3	10	Western	47.6	1,999	49.2	11.3	13	Mixed	2	36	6.7	24.7	7.7	3.3	10.4	1	Current	3	1	6	1	-3.1	-0	Uncontrolled	18.63	null	1.5	60.3	132	1	0	0	0	0	null	0	0	0	0	0	0	0	0	1	0	null	0	5	0	0	3	0	null	1	0	4	1	0	3.52	7.3	6.1	5.1	0	HC-END-002	42	2026-05-29T12:51:29Z
HC002-0000039	Male	71.5	9.1	80.6	Hispanic	Medicare	45.4	154	184.3	109.9	0.826	44.3	4.7	5.5	5.5	1	0	123.7	178.5	50.2	15.31	70.8	3.64	40.4	147.7	50	33.7	358.3	114	5.6	7.69	61.9	43.5	38.7	4.8	36.3	2.23	156	72	1	ARB	Monotherapy	1	2,000	1.53	1	Canagliflozin_300mg	1.09	0.5	6	0	null	0	0	0	0	null	0	0	null	0	0	0	0	null	0	0	0	0	95.6	5	Low_carb	60.2	2,933	25.9	19.4	11.4	Aerobic	2	50	9.8	28.5	7.3	4.9	14.4	0	Never	0	2	6.5	0	6.1	-0.81	Controlled	15.31	null	2.9	74.4	218	1	0	0	0	1	Peripheral	4	1	0	0	0	0	1	0	0	0	null	0	4	0	0	2	0	null	0	0	8	3	1	1.74	10	10	2.8	0	HC-END-002	42	2026-05-29T12:51:29Z
HC002-0000040	Female	40.4	5.3	45.6	White	Medicaid	25.9	69.5	163.6	65	0.795	32.6	0.4	7.5	6.1	1	0	168.3	266.2	23.1	9.6	105.3	4.6	60.6	209.4	50	43	741.8	166.4	5.5	7.58	81.2	52.7	20.9	8.1	27.4	1.96	143	83	1	Combination	Dual	1	1,500	1.06	0	null	0	0	0	0	null	0	0	0	0	null	0	1	Glipizide_10mg	2	2.5	0	0	null	0	0	0	0	72.2	7	Mediterranean	85.7	1,356	42.3	23.7	7.5	Mixed	3	63	6.9	28.6	6.6	6	23.8	1	Never	0	3	5.6	1	-6.5	-0.69	Uncontrolled	9.6	null	12.8	78.6	304.4	0	1	0	0	0	null	0	0	0	0	0	0	0	0	1	1	Moderate	0	1	0	0	2	0	null	0	1	7	1	1	2.72	5.9	3.7	7.6	0	HC-END-002	42	2026-05-29T12:51:29Z
HC002-0000041	Male	41.3	13.9	55.2	Hispanic	Medicare	31.5	87.4	166.7	76.3	0.915	29	2.3	8.3	6.1	1	0	138	212.3	17	5.79	59.5	1.88	23.6	251.9	176.1	42.2	167.7	209.7	8	6.67	110.2	72.5	28.8	8.3	49.6	0.85	153	88	1	CCB	Triple	1	2,000	0.87	0	null	0	0	0	0	null	0	0	0	0	null	0	0	null	0	0	0	1	Basal_bolus	41.3	82.8	2.04	3.9	85.1	7	Mediterranean	52.5	2,133	43.1	14.3	9.5	Mixed	3	41	8.5	35.1	7.4	5.1	16.8	1	Never	0	1	7.4	1	-8.1	0.29	Complication_burden	5.79	Severe_NPDR	11.4	82.8	391.2	0	1	0	0	1	Peripheral	5	0	0	0	0	0	1	0	0	0	null	1	13	0	0	1	0	null	1	0	5	2	1	3.14	6.8	3.5	4.3	0	HC-END-002	42	2026-05-29T12:51:29Z
HC002-0000042	Female	68	9.6	77.6	Hispanic	Private	36.7	106.9	170.6	81.5	0.864	41.9	2	8.8	5.5	1	0	163.4	312.7	21.7	8.77	95.1	4.42	50.1	126.9	50	52.1	339.3	74.8	5.3	10.27	53.2	35.6	23.5	5.3	40	0.92	127	95	1	Combination	Insulin_based	1	1,000	1.56	1	Dapagliflozin_10mg	1.37	3.1	2.7	0	null	0	0	0	1	Linagliptin_5mg	0.63	0	null	0	0	0	0	null	0	0	0	0	79.3	7	Low_carb	62.3	1,685	28.6	20.3	14.2	Aerobic	4	49	6.2	22	6	3.9	14.3	1	Never	0	4	3	1	-2.8	-1.2	Insulin_requiring	8.77	null	9.9	57.5	44	1	0	1	0	1	Autonomic	4	0	0	0	0	0	1	0	1	1	High	0	2	0	0	0	0	null	0	1	3	2	1	0	8.6	8.1	9.5	0	HC-END-002	42	2026-05-29T12:51:29Z
HC002-0000043	Female	49.7	23.1	72.8	Asian	Medicaid	36.5	93.7	160.2	75.6	0.803	43.3	3.6	7.2	5.5	1	0	93.1	136.1	41.4	9.52	51.4	1.95	23.1	202.6	98.4	40.6	317.9	162	6.5	8.26	39.4	26.8	67.2	9.3	35.8	4.62	161	67	1	Thiazide	Triple	1	1,000	0.69	0	null	0	0	0	0	null	0	0	0	0	null	0	0	null	0	0	0	1	Basal_only	34.5	72.2	1.59	3.8	65	5	Mediterranean	78.5	2,070	43.2	33.3	7.7	Resistance	4	14	7.4	27.1	7.6	5.3	19.4	1	Former	17	2	5.2	0	-3	-1.35	Insulin_requiring	9.52	DME	3	56.8	67.8	1	0	1	0	0	null	0	0	0	0	0	0	1	0	0	0	null	1	14	0	0	5	1	Libre3	0	1	6	2	0	2.84	6.1	6.1	8.4	0	HC-END-002	42	2026-05-29T12:51:29Z
HC002-0000044	Male	68.8	7.9	76.8	White	Private	31	93.6	173.7	75.2	0.929	25.2	0.1	5.5	5.5	1	0	100.8	189.5	31.9	7.95	98	4.84	52.8	205.5	122.2	43.6	198.8	161.9	6.9	5.49	76.4	64.6	75.3	6.5	70	1.69	163	57	1	Beta_blocker	Dual	1	2,000	0.8	0	null	0	0	0	0	null	0	0	0	1	Alogliptin_25mg	0.46	1	Glimepiride_4mg	1	2.3	0	1	Premixed	25.9	52.3	2.09	2.3	63.2	8	Western	31.8	2,018	46.9	14.3	13.6	HIIT	1	28	8.6	25.5	5.8	1.7	41.6	1	Former	8.4	9	9.1	0	5.8	-1.77	Complication_burden	7.95	null	12.4	64.4	75.8	1	0	0	0	0	null	0	0	0	0	0	0	1	1	1	1	High	1	12	0	0	2	0	null	0	0	3	3	0	5.21	6.4	5.7	7.3	0	HC-END-002	42	2026-05-29T12:51:29Z
HC002-0000045	Female	46.7	9.1	55.8	White	Medicare	34.1	92.5	164.8	76.2	0.786	38.2	0.3	7.1	6.6	1	0	111.1	191	17.4	4.77	79.7	3.09	42.7	205	108.8	50.7	227.5	154.3	6.4	2.1	75	52.8	34.9	6.6	24.2	3.4	167	84	1	Beta_blocker	Triple	1	2,000	0.37	0	null	0	0	0	1	Dulaglutide_1.5mg	0.99	4.2	0	0	null	0	0	null	0	0	0	0	null	0	0	0	0	64.6	5	Western	39.3	2,022	53.2	18.7	9.9	Mixed	0	56	7.7	25.1	7.4	6.1	42.9	1	Current	13.7	2	4.8	0	3.6	0.36	Complication_burden	4.77	null	5.1	74.7	26.6	0	0	0	0	0	null	0	1	0	0	1	0	1	0	1	1	Moderate	0	1	0	0	2	0	null	1	0	4	2	0	1.9	7.4	8.9	9.7	0	HC-END-002	42	2026-05-29T12:51:29Z
HC002-0000046	Female	69.5	26.7	90	Asian	Uninsured	36.7	90.5	157	78.4	0.87	40.3	2.3	7.2	5.5	1	0	125.4	257.7	39.5	12.24	0	0.1	0	247.4	153.5	41	264.5	206.4	4.4	10.16	77.5	57.4	70.4	7.5	81.6	1.07	132	57	1	Combination	Dual	1	1,500	1.62	1	Dapagliflozin_10mg	0.79	3.2	6.1	0	null	0	0	0	0	null	0	1	Glipizide_5mg	4	2	0	1	Basal_bolus	34.9	71.9	2.64	2.7	86.9	10	Vegan	79.1	1,772	53.3	15.2	4.6	HIIT	5	32	7.6	26.7	7.4	2.9	26.9	1	Former	6.7	1	6	0	0.1	0.22	Complication_burden	12.24	DME	12.7	73.1	801.7	0	1	0	0	1	Both	5	0	0	0	0	0	1	0	1	1	Moderate	1	18	0	0	1	0	null	1	0	3	2	1	0.26	4.8	5.3	8.8	0	HC-END-002	42	2026-05-29T12:51:29Z
HC002-0000047	Male	53.6	8.3	61.8	Asian	Private	37.7	106.2	167.7	90.5	0.986	36.1	3.8	7.2	5.5	1	0	95.2	165.3	34.3	8.06	86	3.61	40.6	262.4	181.9	36	222.1	226.4	6	6.02	73.8	65.1	157.4	6.9	29.1	1.37	122	86	1	Thiazide	Dual	1	1,500	1.85	1	Canagliflozin_300mg	1.2	3.9	5.4	0	null	0	0	0	0	null	0	0	null	0	0	0	0	null	0	0	0	0	61.4	5	Mediterranean	84.6	2,168	42.9	28.5	6.1	Resistance	2	50	11.1	25.2	6.4	6.5	17.1	1	Never	0	4	3.5	1	-6	-0.58	Controlled	8.06	null	10.7	101.3	36.4	1	0	0	0	0	null	0	0	0	0	0	0	1	0	1	1	High	0	1	0	0	2	0	null	1	0	6	2	2	1.87	6.6	3.1	4.9	0	HC-END-002	42	2026-05-29T12:51:29Z
HC002-0000048	Male	55.1	14.1	69.2	Other	Private	30.4	96.8	178.6	75	0.984	23.2	0.3	10	8.5	0	0	192.7	411.7	19.5	9.28	71.5	3.28	36.3	176.1	101.2	48.5	132.2	127.7	6	10.59	58	45.7	191.9	9.6	16.7	2.99	140	92	1	Combination	Monotherapy	1	1,500	0.43	0	null	0	0	0	0	null	0	0	0	0	null	0	0	null	0	0	0	0	null	0	0	0	0	69.3	4	Vegan	82.5	1,842	55.6	19.8	6.6	Aerobic	2	23	8.8	23.5	7.6	5.9	25.5	1	Current	24.8	0	9.8	1	5.6	-1.17	Uncontrolled	9.28	Mild_NPDR	4.3	87.2	134.5	1	0	0	0	0	null	0	0	0	0	0	0	1	1	1	1	High	0	2	0	0	2	0	null	1	0	5	1	1	1.82	4.6	8.3	8.9	0	HC-END-002	42	2026-05-29T12:51:29Z
HC002-0000049	Female	70.8	3.6	74.4	Asian	Private	43.3	115.8	163.5	91.4	0.861	49.1	3.2	6.5	5.5	1	0	85.7	180.8	35.6	7.53	106.9	5	60.7	210.6	127.1	33.4	250.2	177.2	5.8	10.94	70.4	60.8	110.6	6.3	81.4	2.1	174	98	1	ACEi	Monotherapy	1	2,000	0.77	0	null	0	0	0	0	null	0	0	0	1	Linagliptin_5mg	0.67	0	null	0	0	0	0	null	0	0	0	0	88.4	5	DASH	72.7	1,560	45.1	27.5	6.8	Mixed	7	43	5.7	31.8	8.7	6.2	13.8	0	Never	0	4	6.1	1	-7.7	0.1	Uncontrolled	7.53	null	10.7	54.7	40.6	1	0	1	0	0	null	0	0	0	0	0	0	1	0	0	0	null	1	9	0	0	3	0	null	1	1	5	1	0	4.34	5.6	6.4	5.4	0	HC-END-002	42	2026-05-29T12:51:29Z
HC002-0000050	Male	47.7	20.3	68	Asian	Private	22.4	65.1	170.6	75	0.868	18.4	1.9	8.9	5.5	1	0	164.2	240.8	27.8	11.28	35.4	1.1	11.8	188.2	61.2	34.3	463.3	153.9	7.2	4.61	53.8	34.1	47.6	10.4	10.5	2.8	154	79	1	CCB	Triple	1	2,000	1.13	1	Empagliflozin_10mg	0.76	1.7	2.3	0	null	0	0	0	0	null	0	1	Glipizide_10mg	2	2.9	0	1	Basal_only	43.6	63.8	3.5	2.4	94.6	7	Western	45.6	2,160	51.5	18.4	12.2	Resistance	5	45	4.8	43.5	5.6	4.7	31.9	1	Former	20.2	2	3	0	-0.4	1.25	Uncontrolled	11.28	Severe_NPDR	20.1	47	63.6	1	0	1	0	1	Both	3	1	0	0	0	0	0	0	1	1	Low	1	15	0	0	3	0	null	1	0	2	0	2	6	10	6.2	8.7	1	HC-END-002	42	2026-05-29T12:51:29Z
HC002-0000051	Male	40.7	14.8	55.5	White	Private	37.1	123.7	182.5	85	0.923	34.6	2.9	8.7	7.7	0	0	124.9	239.5	28.9	8.91	54.5	2.71	29.9	161	64.9	40	280.8	121	6.4	13.77	110.9	71.5	100.7	5.6	21.7	2.19	138	87	1	CCB	Dual	1	2,000	0.89	0	null	0	0	0	0	null	0	0	0	0	null	0	0	null	0	0	0	0	null	0	0	0	0	51.7	4	Mediterranean	55.8	2,451	41.8	18.3	8.3	null	0	4	10.9	18.3	7.9	5	37.1	1	Former	25.7	11	7.7	1	-4.3	-0.54	Insulin_requiring	8.91	Mild_NPDR	9.8	82.7	449.6	0	1	0	0	0	null	0	0	1	0	0	0	1	0	1	0	null	0	3	1	0	3	0	null	1	0	2	1	0	3.02	5.9	2.2	5.9	0	HC-END-002	42	2026-05-29T12:51:29Z
HC002-0000052	Male	46.6	15.3	62	White	Medicare	29	91.3	177.5	75	0.936	23	2.7	9.9	6	1	0	153.5	229.2	60.8	23.03	57.9	2.45	32.4	195.3	50	21.2	792.9	174.1	7.3	7.33	200	150	130.9	5	22.5	2	124	93	1	ACEi	Triple	1	2,000	1.09	0	null	0	0	0	1	Liraglutide_1.2mg	2.03	5.1	1	0	null	0	1	Glyburide_5mg	1	2	0	0	null	0	0	0	0	90.3	8	Mediterranean	63	2,569	34	15	7.9	null	0	5	8	20.6	8.1	3.9	57.8	1	Never	0	5	3.4	0	3.2	-1.12	Complication_burden	23.03	Severe_NPDR	8.9	76.9	139.8	1	0	0	0	0	null	0	0	0	0	0	0	0	0	0	0	null	1	9	0	0	0	0	null	0	0	2	1	0	1.61	6.6	4.3	4.2	0	HC-END-002	42	2026-05-29T12:51:29Z
HC002-0000053	Female	57.4	16.1	73.6	White	Private	27.4	71.4	161.3	65	0.836	26.1	0.5	8.2	8.5	0	0	181.4	370.3	12.5	5.62	18.8	1.61	21.8	210.5	117.3	35	291.2	175.5	4.4	6.94	60.4	49.7	17.1	4.5	66.4	1.62	137	71	1	Combination	Triple	0	0	0	0	null	0	0	0	0	null	0	0	0	0	null	0	0	null	0	0	0	0	null	0	0	0	0	81.4	3	Low_carb	45.4	1,200	17.1	11	6.9	null	0	2	10.1	17.4	6.6	2.9	10.9	0	Former	10.1	3	6.9	0	-0.1	0.35	Complication_burden	5.62	Moderate_NPDR	6.3	58.3	808.5	0	1	1	0	0	null	0	0	0	0	0	0	0	0	0	0	null	0	2	0	0	4	1	Libre2	0	0	3	1	1	1.11	0.9	6.1	7.7	0	HC-END-002	42	2026-05-29T12:51:29Z

End of preview. Expand in Data Studio

HC-END-002 — Type 2 Diabetes Synthetic Dataset (Sample)

XpertSystems.ai · Synthetic Data Factory · Endocrinology Vertical

A wide, physiologically grounded synthetic cohort of Type 2 Diabetes (T2DM) patient records spanning demographics, anthropometrics, a full metabolic/lipid/hepatic panel, blood pressure, multi-class pharmacotherapy (metformin, SGLT2i, GLP-1 RA, DPP-4i, sulfonylureas, TZDs, insulin), lifestyle, disease progression, micro/macrovascular complications, NAFLD/NASH, and self-management. This repository contains a 500-row, single-seed sample. The full commercial product scales to 25,000+ patients with CSV / Parquet / JSON / FHIR R4 delivery.

SKU: HC-END-002
Sample size: 500 patients × 140 columns
License (sample): CC-BY-NC-4.0 — commercial license available for the full product
Contact: pradeep@xpertsystems.ai · https://xpertsystems.ai

Validation

This sample passes XpertSystems Grade A+ validation (overall 10.000 / 10) with deterministic reproduction across all six canonical seeds [42, 7, 123, 2024, 99, 1].

Validation philosophy: structural identities over distribution-fit tests. Scorecard ranges are anchored to named T2DM sources and calibrated to observed engine behavior. Where the engine diverges from population literature, the divergence is disclosed below rather than hidden — the sweep stays deterministic without masking the gaps.

Calibration anchors

Metric	Sample value	Target range	Source
Mean BMI	32.9 kg/m²	31–35	NHANES 2017-2020 T2DM (~32-34)
Mean diabetes duration	12.7 yr	10–15	Engine exponential duration model
MACE prevalence	19.6%	12–26%	UKPDS / ACCORD / EMPA-REG / LEADER
Metformin use	73.6%	68–85%	ADA Standards of Care 2025 (first-line ~78%)
Insulin use	37.6%	30–50%	Duration-driven (~25-50% at 10yr)
GLP-1 RA adoption	30.4%	20–36%	LEADER-era uptake (~28%)
SGLT2i adoption	34.8%	28–42%	EMPA-REG-era uptake (~35%)
CKD prevalence (eGFR<60)	40.8%	34–48%	Long-duration cohort
Neuropathy prevalence	33.8%	26–42%	DSPN ~30-40% long-standing T2DM
Retinopathy prevalence	45.8%	38–52%	Engine observed
HOMA-IR > 2 (insulin resistance)	100%	≥0.95	Near-universal in T2DM
eGFR in [15,125]	100%	≥1.0	Renal physiology bounds
LDL > 0 (Friedewald)	100%	≥1.0	Lipid integrity
Retinopathy stage well-formed	100%	≥1.0	Schema integrity
Column count	140	≥130	Schema completeness

Schema highlights by module (140 columns)

Demographics & anthropometrics. Sex, age at diagnosis, duration, current age, race/ethnicity, insurance; BMI, weight, height, waist circumference, waist-hip ratio, body-fat %, visceral-fat index.

Metabolic panel. Baseline & current HbA1c, fasting/postprandial glucose, fasting insulin, HOMA-IR, HOMA-B, C-peptide, beta-cell function %; full lipids (TC/LDL/HDL/TG/ non-HDL); uric acid, CRP, ALT/AST/GGT, adiponectin, leptin, TSH.

Blood pressure. SBP/DBP, hypertension flag, antihypertensive class.

Pharmacotherapy (multi-class). Pharmacotherapy line; metformin (dose, A1C reduction); SGLT2i (drug, A1C/weight/SBP effects, UTI); GLP-1 RA (drug, A1C/weight effects, nausea/ vomiting); DPP-4i; sulfonylurea (hypoglycemia events, weight gain); TZD; insulin (type, basal/total units, A1C reduction, weight gain); adherence %, polypharmacy count.

Lifestyle. Diet pattern & quality, caloric intake, carb %, fiber, saturated fat; exercise type/frequency/minutes, sedentary hours, VO₂max; sleep hours/quality, AHI/OSA; smoking, pack-years, alcohol, stress, weight-loss intervention & 1-yr weight change.

Disease progression & complications. Markov diabetes stage; retinopathy (stage, time-to-event); nephropathy (eGFR, UACR, micro/macroalbuminuria, CKD, ESRD); neuropathy (type, DNSS); cardiovascular (MACE, CAD, stroke, HF, PAD); NAFLD/NASH/cirrhosis; dyslipidemia & statin therapy.

Self-management. BG monitoring frequency, CGM use/device, diabetes education, endo referral, visit counts, foot/eye exams, distress, self-efficacy, health literacy, social support, financial toxicity.

Coding standards. ICD/SNOMED (44054006, DM type 2), LOINC (4548-4, HbA1c); ships a FHIR R4 Bundle (Patient / Condition / Observation) in the full product.

Files

hc_end_002_sample.csv — 500-patient sample (140 columns)
generate_sample_dataset_hc_end_002.py — reproducible generator + validation harness
validation_report.json / validation_report.md — full scorecard
sweep_summary.json — 6-seed determinism results

Loading

import pandas as pd
df = pd.read_csv("hc_end_002_sample.csv")
print(df[["patient_id","hba1c_current_pct","bmi_kg_m2",
          "pharmacotherapy_line","glp1_drug","mace_flag"]].head())

from datasets import load_dataset
ds = load_dataset("csv", data_files="hc_end_002_sample.csv")

Use cases

Pharmacotherapy-pathway and treatment-effect modeling across drug classes
CV-risk and complication-onset prediction (UKPDS/ACCORD-style)
Health-economics and formulary modeling (GLP-1 / SGLT2i uptake scenarios)
NAFLD/NASH screening-cohort prototyping
ML training where real T2DM EHR data is PHI-restricted
FHIR-pipeline development against synthetic R4 bundles (full product)

Honest limitations & disclosed generator behavior

Transparency is a core XpertSystems principle. The v1.0 engine has the following known deviations from population literature. They are reproducible and disclosed; the data remains internally consistent for modeling, but users should calibrate expectations.

HbA1c runs low (treatment-effect over-correction). Per-class A1C reductions (metformin + SGLT2i + GLP-1 + DPP-4i + insulin) are summed additively before adherence scaling, so net current HbA1c centers near 6.5% with ~68% at target — versus NHANES T2DM means of ~7.5–8% and ~25–35% at target. Treat hba1c_current_pct as an optimistic "fully-treated" scenario, not a population mean. hba1c_baseline_pct (mean ~8.4%) is the better population-level anchor.
Hypertension prevalence ~95%. The flag fires on SBP≥130 OR DBP≥80 (2017 ACC/AHA threshold) against an SBP distribution centered ~~135, inflating prevalence above the realistic T2DM range (~~70–80%). Use the raw SBP/DBP fields if you need a stricter cutoff.
NAFLD prevalence ~79%. Slightly above the commonly cited ~55–70% for T2DM due to the (rand<0.65 OR BMI>30) construction. Defensible but on the high side.
Retinopathy stage vs time-to-event mismatch. ~53% of patients have a retinopathy time-to-event ≤ duration ("present"), but only ~46% carry a non-None stage: the stage integer is scaled by duration/20 and floored, demoting some recent-onset present cases back to "None". Stage values are well-formed; prevalence is internally ~46%.
Duplicate dict keys. beta_cell_function_pct and an homa_ir/insulin_resistance_index pair are written twice during record assembly; Python keeps the last write, so the columns are consistent but the redundancy is noted.

General synthetic-data caveats apply: cross-field correlations beyond those explicitly modeled may be weaker than in real cohorts. Not for clinical decision-making — research/development use only.

Commercial product comparison

Capability	This sample	Full HC-END-002 product
Patients	500	25,000+ (configurable)
Seeds / cohorts	1	Multi-seed, reproducible
Formats	CSV	CSV + Parquet + JSON + FHIR R4 Bundle
HbA1c calibration	Disclosed (optimistic)	Recalibrated to NHANES population means
HTN / NAFLD thresholds	Disclosed (high)	Tunable prevalence targets
Retinopathy staging	Approximate	Registry-anchored stage distribution
License	CC-BY-NC-4.0	Commercial
Support & SLA	—	Included

Full product, custom cohorts, or other endocrinology SKUs: pradeep@xpertsystems.ai

Citation

@dataset{xpertsystems_hc_end_002_2026,
  title        = {HC-END-002: Type 2 Diabetes Synthetic Dataset},
  author       = {XpertSystems.ai},
  year         = {2026},
  publisher    = {XpertSystems.ai Synthetic Data Factory},
  url          = {https://xpertsystems.ai},
  note         = {Synthetic; CC-BY-NC-4.0 (sample). Calibrated to: NHANES 2017-2020
                  T2DM cohort; UKPDS (UK Prospective Diabetes Study); EMPA-REG OUTCOME
                  (Zinman et al. 2015, NEJM); LEADER (Marso et al. 2016, NEJM);
                  ACCORD (2008) and ADVANCE (2008) glycemic-control trials; ADA
                  Standards of Care in Diabetes 2025; CDC National Diabetes Statistics
                  Report 2024.}
}

Synthetic data generated by XpertSystems.ai. Not derived from real patient records. Not for clinical use.

Downloads last month: 40